Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A permeable reactive barrier (PRB) was installed in Aznalcóllar (Spain) in order to rehabilitate the Agrio aquifer groundwater severely contaminated with acid mine drainage after a serious mining accident. The filling material of the PRB consisted of a mixture of calcite, vegetal compost and, locally, Fe(0) and sewage sludge. Among the successes of the PRB are the continuous neutralisation of pH and the removal of metals from groundwater within the PRB (removals of >95%). Among the shortcomings are the improper PRB design due to the complexity of the internal structure of the Agrio alluvial deposits (which resulted in an inefficient capture of the contaminated plume), the poor degradability of the compost used and the short residence time within the PRB (which hindered a complete sulphate reduction), the clogging of a section of the PRB and the heterogeneities of the filling material (which resulted in preferential flows within the PRB). Undoubtedly, it is only through accumulated experience at field-scale systems that the potentials and limits of the PRB technology can be determined.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11356-013-1507-2DOI Listing

Publication Analysis

Top Keywords

prb
9
permeable reactive
8
reactive barrier
8
acid mine
8
mine drainage
8
filling material
8
performance field-scale
4
field-scale permeable
4
barrier based
4
based organic
4

Similar Publications

There is growing interest in understanding the mechanisms underlying differences in cancer incidence among species (comparative oncology). The naked mole-rat (NMR) is often referenced as "cancer-resistant" and prior studies focused on identifying mechanisms explaining this. However, efforts to assess this in vivo have been limited.

View Article and Find Full Text PDF

Background: Among people with cystic fibrosis, sweat chloride and lung function response to elexacaftor-tezacaftor-ivacaftor (ETI) is variable. We hypothesised that the presence of two versus one ETI-responsive CFTR variant could predict response variability.

Methods: In this analysis of two real-world observational studies, data from a French national cohort of adults (aged ≥18 years) with cystic fibrosis and at least one F508del variant treated with ETI and the French compassionate programme for ETI in people (aged ≥6 years) with cystic fibrosis without F508del were used to examine sweat chloride concentrations (SCCs) after ETI initiation, and the absolute change in SCC and percentage of predicted forced expiratory volume in 1 s (ppFEV) following ETI initiation.

View Article and Find Full Text PDF

Multitargeting neuroimmune pathways: novel candidates for chronic pain relief.

Trends Pharmacol Sci

September 2025

Instituto de Investigaciones en Medicina Traslacional CONICET-Universidad Austral, Buenos Aires, Argentina; Facultad de Ciencias Biomédicas, Universidad Austral, Buenos Aires, Argentina. Electronic address:

Chronic pain remains inadequately managed, partly because of insufficient consideration of neuroimmune interactions in therapeutic design and a continued reliance on single-target strategies ill-suited to its complexity. Multitarget-directed ligands that modulate the non-neuronal microenvironment of neuronal pain pathways show promise, supported by encouraging preclinical data and initial clinical findings.

View Article and Find Full Text PDF

Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors.

Front Oncol

August 2025

Tennessee Valley Healthcare System (TVHS) Department of Veterans Affairs, Nashville, TN, United States.

Introduction: Inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) are approved for the treatment of locally advanced or metastatic breast cancer, but not for melanoma.

Methods: In this study, we evaluated the effectiveness of the CDK4/6 inhibitor, palbociclib, the CDK2 inhibitor, PF-07104091, the dual CXCR1 and CXCR2 (CXCR1/2) antagonist, SX-682, and the combination of these inhibitors for effective treatment of melanoma in preclinical models.

Results: Both palbociclib and SX-682 inhibited the growth of BRAF/NRAS B16-F10 and NRAS 1014 melanoma tumors and in both models, SX-682 created a more anti-tumor immune microenvironment.

View Article and Find Full Text PDF

Large-cell neuroendocrine carcinoma (LCNEC) can be genomically subtyped into small cell lung cancer (SCLC)- and non-SCLC (NSCLC)-like. NEUROD1, ASCL1, POU2F3, and YAP1 (NAPY) subtypes have been reported for SCLC. We immunohistochemically evaluated NAPY in LCNEC alongside relevant protein expression data.

View Article and Find Full Text PDF